Artelo Biosciences to Present at the Q4 Investor Summit on November 17th
Solana Beach, California--(Newsfile Corp. - November 11, 2021) - Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage pharmaceutical company developing therapeutics that modulate endogenous signaling pathways, including the endocannabinoid system, today announced that management will present at the Q4 Investor Summit, hosted by the Investor Summit Group, being held virtually on November 16-17, 2021.
Gregory Gorgas, President and Chief Executive Officer of Artelo Biosciences, is scheduled to present as follows:
|Event:||Q4 Investor Summit|
|Date and Time:||Wednesday, November 17 at 2:45 pm Eastern Time|
A replay of the presentation will be available on the Investor Relations section of the Company website here. Mr. Gorgas will also host one-on-one meetings with investors throughout the conference.
To register for the conference, please visit www.investorsummitgroup.com.
About the Investor Summit
The Investor Summit is an exclusive, independent conference dedicated to connecting small cap and microcap companies with qualified investors. The Q4 Investor Summit will take place virtually, featuring 80+ companies and over 800 investors, consisting of institutional investors, family offices, and private wealth.
For more information, please contact Sasha Murray at email@example.com.
About Artelo Biosciences
Artelo Biosciences, Inc. is a clinical stage pharmaceutical company dedicated to the development and commercialization of proprietary therapeutics that target lipid signaling pathways, including the endocannabinoid system. Artelo is rapidly advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, PTSD, pain, and inflammation. Led by proven pharmaceutical executives collaborating with highly respected researchers and technology experts, Artelo applies leading edge scientific, regulatory, and commercial discipline to develop high-impact therapies. More information is available at www.artelobio.com and Twitter: @ArteloBio.
Investor Relations Contact:
Crescendo Communications, LLC
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/102959